Use the Search Fields to Find Information
Page 51 of 375
The Cannabinoid Receptor Agonist THC Attenuates Weight Loss in a Rodent Model of Activity-Based Anorexia
Abstract Anorexia nervosa (AN) is characterized by anhedonia whereby patients experience little pleasure or reward in many aspects of their lives. Reward pathways and the
September 4, 2024
The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells
Deregulation of cell survival pathways and resistance to apoptosis are widely accepted to be fundamental aspects of tumorigenesis. As in many tumours, the aberrant growth
September 19, 2019
The Cannabinoid Delta-9-tetrahydrocannabinol Disrupts Estrogen Signaling in Human Placenta
Abstract Cannabis consumption is increasing worldwide either for recreational or medical purposes. Its use during gestation is associated with negative pregnancy outcomes such as, intrauterine
May 30, 2024
The cannabinoid D9 -tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity
BACKGROUND: Cannabinoid type-1 (CB1) receptor inverse agonists improve type 2 diabetes and dyslipidaemia but were discontinued due to adverse psychiatric effects. D9 -Tetrahydrocannabivarin (THCV) is
September 19, 2019
The cannabinoid CB2 receptor mediates the analgesic effects of Cannabis sativa extract in a rat model of neuropathic pain
Please use this link to access this publication. Abstract Neuropathic pain (NP) is a complex and debilitating condition that is often refractory to currently available
May 2, 2025
The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence
Please use this link to access this publication. Abstract The opioid crisis has underscored the urgent need to identify safe and effective therapeutic strategies to
September 25, 2025
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling
We have recently reported that in bone the cannabinoid CB1 receptor is present in sympathetic terminals. Here we show that traumatic brain injury (TBI), which
September 19, 2019
The Cannabinoid CB1 Receptor in Schizophrenia
Please use this link to access this publication. Abstract Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may
March 25, 2024
The Cannabinoid Agonist Win55212 Reduces Brain Damage in an In Vivo Model of Hypoxic-Ischemic Encephalopathy in Newborn Rats
Neonatal hypoxic-ischemic encephalopathy (NHIE) is a devastating condition for which effective therapeutic treatments are still unavailable. Cannabinoids emerge as neuroprotective substances in adult animal studies;
September 19, 2019
The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain
Abstract Objective To assess the analgesic efficacy and safety of single-dose oral cannabidiol (CBD) as an adjunct to standard care for patients presenting to an
April 23, 2024
Page 51 of 375